Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
18,424,425
-
Share change
-
+11,751,775
-
Total reported value
-
$60,969,066
-
Price per share
-
$3.31
-
Number of holders
-
28
-
Value change
-
+$38,560,009
-
Number of buys
-
12
-
Number of sells
-
18
Institutional Holders of CTI BIOPHARMA CORP - COM (CTIC) as of Q2 2017
As of 30 Jun 2017,
CTI BIOPHARMA CORP - COM (CTIC) was held by
28 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,424,425 shares.
The largest 10 holders included
BVF INC/IL, ORBIMED ADVISORS LLC, Stonepine Capital Management, LLC, VANGUARD GROUP INC, Alyeska Investment Group, L.P., BlackRock Inc., SUSQUEHANNA INTERNATIONAL GROUP, LLP, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, and TIEDEMANN WEALTH MANAGEMENT, LLC.
This page lists
28
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.